Report overview
This report aims to provide a comprehensive presentation of the global market for Non-Insulin Therapies for Diabetes, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Insulin Therapies for Diabetes. This report contains market size and forecasts of Non-Insulin Therapies for Diabetes in global, including the following market information:
Global Non-Insulin Therapies for Diabetes Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Non-Insulin Therapies for Diabetes market was valued at US$ 32870 million in 2022 and is projected to reach US$ 58240 million by 2030, at a CAGR of 8.5% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Alpha-glucosidase Inhibitors Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Non-Insulin Therapies for Diabetes include GSK, Eli Lilly, Sumitomo Dainippon Pharma, Intarcia Therapeutics, Servier, Pfizer, Merck, Dong-A Pharmaceutical and Luye Pharma Group, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-Insulin Therapies for Diabetes companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Insulin Therapies for Diabetes Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Non-Insulin Therapies for Diabetes Market Segment Percentages, by Type, 2022 (%)
Alpha-glucosidase Inhibitors
Amylin Agonists
Biguanides
Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Glinides / Meglitinides
GLP-1 Analogs / GLP-1 Agonists
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Sulfonylureas
Thiazolidinediones
Others
Global Non-Insulin Therapies for Diabetes Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Non-Insulin Therapies for Diabetes Market Segment Percentages, by Application, 2022 (%)
Monitoring
Diagnosis
Treatment
Others
Global Non-Insulin Therapies for Diabetes Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Non-Insulin Therapies for Diabetes Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Insulin Therapies for Diabetes revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-Insulin Therapies for Diabetes revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
GSK
Eli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Pfizer
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
3SBio
Jiangsu Hengrui Medicine
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-Insulin Therapies for Diabetes, market overview.
Chapter 2: Global Non-Insulin Therapies for Diabetes market size in revenue.
Chapter 3: Detailed analysis of Non-Insulin Therapies for Diabetes company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-Insulin Therapies for Diabetes in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
